Open Label Study of BAY1082439 in Patients With Advanced Cancer

Neoplasms Clinical Trial

Official title:

An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01728311
• Other study ID #: 15734
• Status: Completed
• Phase: Phase 1
• First received: November 7, 2012
• Last updated: January 29, 2018
• Start date: November 21, 2012
• Est. completion date: February 6, 2017

Study information

• Verified date: January 2018
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability and the pharmacokinetics of BAY1082439

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: February 6, 2017
• Est. primary completion date: June 3, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Subjects with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and / or if in the judgment of the investigator, experimental treatment is clinically and ethically acceptable

• Expansion phase only: Subjects with histologically or cytologically confirmed, locally advanced or metastatic endometrial cancer or breast cancer or iNHL, who are refractory to or have exhausted all available therapies

• International normalized ratio (INR) and partial thromboplastin time (PTT) <1.5 x ULN [Subjects on anticoagulation with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.] For subjects on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre-dose, as defined by the local standard of care

• Measurable or evaluable disease

• Life expectancy of at least 12 weeks

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

• Adequate bone marrow, liver and renal function

Exclusion Criteria:

• History of cardiac disease: congestive heart failure > New York Heart Association (NYHA) Class II, unstable angina (anginal symptoms at rest), new-onset angina (within the past 3 months prior to the first dose of study drug), myocardial infarction within the past 6 months prior to the first dose of study drug, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

• Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management

• History of diabetes mellitus or gestational diabetes mellitus

• Fasting blood glucose level >125 mg/dL or HbA1c 7% at screening

• Active clinically serious infections > Grade 2

• History of organ allograft

• Seizure disorder requiring therapy (such as steroids or anti-epileptics)

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• BAY1082439
BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Korea, Republic of,  Singapore,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events as a measure of safety and tolerability		Up to 2 years
Primary	Maximum tolerated dose of BAY1082439		Up to 1 year
Primary	Maximum observed plasma concentration (Cmax) of BAY1082439 after a single dose		Serial PK samples will be selected during cycle 1 day 1 (pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose) and sparse samples during the rest of the cycle as well as in cycle 2
Primary	Time to Cmax (tmax) of BAY1082439 after a single dose		Serial PK samples will be selected during cycle 1 day 1 (pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose) and sparse samples during the rest of the cycle as well as in cycle 2
Primary	Area under the plasma concentration-time curve (AUC[0-t]) of BAY1082439 after a single dose		Serial PK samples will be selected during cycle 1 day 1 (pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose) and sparse samples during the rest of the cycle as well as in cycle 2
Secondary	Area under the concentration-time curve over the dosing interval (AUC[0-tau])		PK parameters following single and repeat-dose administration in cycle 1
Secondary	Maximum observed concentration (Cmax)		PK parameters following single and repeat-dose administration in cycle 1
Secondary	Time of occurrence of Cmax (tmax)		PK parameters following single and repeat-dose administration in cycle 1
Secondary	Terminal phase half-life (t1/2)		PK parameters following single and repeat-dose administration in cycle 1
Secondary	Tumor response based on Response Evaluation Criteria in Solid Tumors, Version 1.1		Up to 2 years

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer products.